星空无限传媒

Chances are that you鈥攐r one of the two people closest to you right now鈥攊s carrying Staphylococcus aureus, even if you鈥檝e never noticed it.

About one in three people harbor the bacterium on their skin or in their nasal passages without any symptoms. Yet in hospitals and other vulnerable settings, this ordinarily harmless microbe can turn dangerous, causing severe infections and pneumonia that are increasingly difficult to treat as antibiotic resistance spreads. Why S. aureus usually coexists peacefully with its human hosts鈥攂ut sometimes becomes deadly鈥攔emains one of the most enduring puzzles in infectious disease research.

LSU microbiologist Chen Chen is tackling this question head-on, investigating how S. aureus subtly manipulates the human immune system to maintain a fragile balance with its host鈥攐ne that can quickly tip from peaceful coexistence into life-threatening disease.

When immune defense becomes immune damage

Each year, S. aureus causes an estimated 50,000 cases of pneumonia in the United States alone, including many ventilator-associated infections in intensive care units. The threat is magnified by the prevalence of methicillin-resistant S. aureus (MRSA) and the emergence of strains resistant even to last-line antibiotics. Despite decades of effort, there is still no approved vaccine.

Part of the challenge, Chen explains, is that S. aureus is not a 鈥渃lassic鈥� pathogen. 鈥淢ost of the time, this bacterium lives with us without causing disease; we call it colonization鈥� she says. 鈥淎nd this is an evolutionary mechanism of spreading; if it were infectiously aggressive and always killed the host, it would be a dead end for the microbe too.鈥�

The immune system plays a central role in determining which path the interaction takes. Neutrophils鈥攚hite blood cells that serve as the body鈥檚 first responders鈥攁re especially important. They migrate rapidly to sites of infection, engulf bacteria, and release antimicrobial enzymes. But that power comes at a cost.

鈥淚n the lung, neutrophils are a double-edged sword,鈥� Chen says. 鈥淭hey are essential for clearing bacteria, but if too many arrive or stay too long, they damage healthy tissue. In severe pneumonia, it鈥檚 often the immune response itself鈥攏ot just the bacteria鈥攖hat causes the most harm.鈥�

So why does the immune system often look the other way, letting S. aureus ride along unnoticed?

Decoding bacterial immune 鈥渂rakes鈥�

Supported by an NIH R01 grant, the project focuses on a family of S. aureus proteins known as superantigen-like proteins, or SSLs. Unlike true superantigens鈥攚hich overstimulate the immune system and can trigger dangerous 鈥渃ytokine storms,鈥� floods of immune signaling molecules that drive excessive inflammation鈥擲SLs do the opposite: they dial the immune response down.

Chen鈥檚 team recently discovered that one member of this family, SSL11, can effectively bring neutrophils to a halt. Instead of migrating toward infection signals, neutrophils exposed to SSL11 become overly adhesive, spreading out and sticking in place. The cells are not activated to attack鈥攂ut they also cannot move.

鈥淚t鈥檚 almost like putting a stop sign on neutrophil migration,鈥� Chen says.

This insight forms the backbone of the new R01 grant. The project has three interconnected aims. First, the researchers will dissect the molecular mechanism behind SSL11鈥檚 effects, identifying how the protein interacts with specific integrins鈥攁dhesion molecules on the neutrophil surface鈥攖o arrest cell movement. 

Second, the team will examine how SSL proteins shape the balance between colonization and infection. Using mouse models, they will compare normal S. aureus strains with genetically engineered strains lacking SSL genes. By tracking bacterial persistence, immune responses, and disease severity, the researchers hope to understand how these immune-modulating proteins help S. aureus quietly colonize hosts without triggering full-blown disease.

Crucially, the project also incorporates a colonization-first model, reflecting the reality that most humans encounter S. aureus early in life and carry it long before any infection occurs. 鈥淢ost animal infection models start with a completely na茂ve host,鈥� Chen says. 鈥淭hat鈥檚 not how things work in people. We want to mimic the human situation as closely as possible.鈥�

The third aim explores a more translational question: could SSL11鈥攐r a modified version of it鈥攂e used therapeutically to protect against severe pneumonia?

From bacterial strategy to therapeutic insight

Preliminary data suggest that timing is key. When SSL11 is given before a severe lung infection in animal models, it appears to limit excessive neutrophil infiltration, reduce lung damage, and lower bacterial burden. Administered at the wrong time, however, immune suppression could be harmful.

鈥淭hat fine balance is exactly what we鈥檙e trying to understand,鈥� Chen says. 鈥淭he goal is not to shut down immunity, but to prevent it from going into overdrive.鈥�

If successful, the research could open the door to an entirely new approach to treating inflammatory lung diseases鈥攐ne inspired by bacterial evolution itself. Rather than killing bacteria outright, future therapies might focus on modulating the host response, reducing tissue damage while allowing the immune system to do its job more effectively.

Beyond pneumonia, the findings could help explain why decades of vaccine development against S. aureus have struggled. By actively manipulating both innate and adaptive immunity, the bacterium may prevent the immune system from forming durable protective memory.

鈥淭his project is really about understanding the rules of engagement between S. aureus and the immune system,鈥� Chen says. 鈥淥nce we understand those rules, we can start thinking more creatively about how to intervene.鈥�